PBAC's latest decision on Adrenaline: Deferred (2018). Considered for Self-administered intramuscular injection for emergency treatment of anaphylaxis in adults and juveniles.
PBAC outcome
Deferred
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
4
first 2016
Submissions
4
2016 → 2018
Eligible population
Adults and juveniles currently prescribed or likely to be prescribed an adrenaline auto-injector for emergency treatment of anaphylaxis.
Therapy area
Immunology
Line of therapy
Not applicable
Evidence base
Single-arm
Primary endpoint
Usability
Pivotal trial size
90 patients
Comparator
EpiPen
Economic model
Not modelled
ICER note
No economic evaluation conducted; this is a minor submission regarding brand equivalence and listing conditions only.
Submission history
Mar 2016: Not recommended · Not applicable
Jul 2016: Recommended · Restricted
Mar 2018: Recommended with restriction · Authority Required